Ubs Oconnor LLC Alnylam Pharmaceuticals, Inc. Transaction History
Ubs Oconnor LLC
- $1.51 Billion
- Q4 2024
A detailed history of Ubs Oconnor LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 10,000 shares of ALNY stock, worth $2.44 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$2.44 Million% of portfolio
0.14%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
670Shares Held
112MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$4.04 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.1 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.33 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.7 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.07 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...